Objective: The objective of this study was to estimate the 10-year clinical benefits and economic value of weight loss in a Swedish population with obesity using a value of weight-loss simulation model.
Methods: Data on the prevalence of and costs associated with obesity and obesity-related complications (ORCs) were applied within an adapted simulation model to evaluate weight-loss benefits for a 2023 Swedish population over 10 years. The 10-year incidence of 10 ORCs and treatment costs in a random cohort of 10,000 individuals were estimated for a stable weight scenario and four weight-loss (5%-20%) scenarios.
Results: The model included 887,272 individuals with obesity aged 20 to 60 years. Hypertension (24.1%), asthma (20.9%), dyslipidemia (18.3%), and type 2 diabetes (10.6%) were highly prevalent. For 10,000 individuals, a 5% to 20% weight loss was estimated to prevent ORCs over 10 years, leading to annual savings between 9.0 million Swedish krona (SEK)/€0.8 million (5% weight loss) and 30.0 million SEK/€2.6 million (20%) by 2033.
Conclusions: Annual treatment costs of ORCs in Sweden will double over 10 years, and weight loss would be associated with significant savings because of the reductions in the incidence of ORCs. Therefore, there is an urgent need to effectively treat obesity to prevent morbidity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/oby.24232 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of clinical benefits and economic value of weight loss in a Swedish population using a simulation model.
Obesity (Silver Spring)
March 2025
School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Objective: The objective of this study was to estimate the 10-year clinical benefits and economic value of weight loss in a Swedish population with obesity using a value of weight-loss simulation model.
Methods: Data on the prevalence of and costs associated with obesity and obesity-related complications (ORCs) were applied within an adapted simulation model to evaluate weight-loss benefits for a 2023 Swedish population over 10 years. The 10-year incidence of 10 ORCs and treatment costs in a random cohort of 10,000 individuals were estimated for a stable weight scenario and four weight-loss (5%-20%) scenarios.
A 73-year-old man presented with a 2-week history of intermittent right-sided chest pain, cough, and progressive dyspnea on exertion. He reported subjective weight loss and anorexia with early satiety over the preceding months. He denied any fevers, night sweats, or sick contacts.
View Article and Find Full Text PDFA 52-Year-Old Woman With Shortness of Breath and Left Lower Back Pain.
Chest
March 2025
Department of Pulmonary and Critical Care Medicine, The University of Toledo, Toledo, OH.
A 52-year-old woman presented to the clinic with progressively worsening shortness of breath associated with intermittent pleuritic left lower back pain for the past 6 months. The patient denied any cough, hemoptysis, fever, chills, or weight loss. She had a history of smoking cigarettes for more than 10 years but quit almost 20 years ago.
View Article and Find Full Text PDFStudy of synergistic effect of pre-enzyme treatment and dielectric barrier discharge plasma for surface modification of cellulosic textile polymer.
Int J Biol Macromol
March 2025
Manipal University Jaipur, Dhemi kalan, 302004 Jaipur, Rajasthan, India. Electronic address:
This study delves into the synergistic effect of Dielectric Barrier Discharge (DBD) plasma and cellulase enzymatic treatment on enhancing the hydrophilicity of sustainable cellulosic biopolymer named Banana (B). The investigation encompasses two approaches: plasma treatment preceded by enzyme (PE) treatment and enzyme treatment preceded by plasma (EP) treatment, both aimed at augmenting to improve the hydrophilicity of biopolymer, which ultimately increases its antimicrobial finish. The study explores the physiochemical transformation that occurred during the treatments including wicking test, contact angle, weight loss, SEM, ATR-FTIR and XRD analyses.
View Article and Find Full Text PDFPreclinical evaluation of several polymeric micelles identifies Soluplus®-docetaxel as the most effective candidate in multiple glioblastoma models.
J Control Release
March 2025
Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Passeig de la Vall d'Hebron, 119-129, 08035 Barcelona, Spain; Functional Validation & Preclinical Research (FVPR)/U20 ICTS Nanbiosis, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain; Department of Pharmacy and Pharmaceutical Technology and Physicochemistry, Faculty of Pharmacy and Food Sciences, School of Pharmacy, Universitat de Barcelona (UB), Av. de Joan XXIII, 27-31, 08028 Barcelona, Spain. Electronic address:
Glioblastoma multiforme (GBM) is one of the most lethal cancers, with limited treatment options due to the blood-brain barrier (BBB), systemic toxicity, and treatment resistance. Nanomedicine offers potential solutions to these challenges. This study explores Pluronic® F127 and Soluplus®-based micelles as carriers for Lomustine, Gefitinib, and Docetaxel to determine the optimal system for GBM therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!